Recursion Completes Merger with Exscientia, Expanding AI Drug Discovery Platform

The merger of AI-driven drug discovery companies Recursion (Nasdaq: RXRX) and Exscientia has been finalized, making Exscientia a wholly owned subsidiary of Recursion. This integration establishes a vertically integrated platform for drug discovery. As part of the merger, Exscientia's ADSs (Nasdaq: EXAI) have ceased trading and are being delisted.

Recursion CEO Chris Gibson highlighted the expanded pipeline, which includes over 10 clinical/preclinical programs and significant partnerships with milestones exceeding $450M so far. Exscientia’s former CEO David Hallett emphasized the merger's ability to accelerate drug discovery through proprietary data and iterative modeling.